Search

Displaying results 3521 - 3530 of 4437 in total
  1. Drug

    Reproxalap

    go.drugbank.com/drugs/DB16688
    Investigational

    Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis

  2. Drug

    AVR-RD-01

    go.drugbank.com/drugs/DB17651
    Investigational

    AVR-RD-01 is an investigational _ex vivo_ lentiviral gene therapy developed by AVROBIO Inc.

  3. Drug

    Avenciguat

    go.drugbank.com/drugs/DB18882
    Investigational

    Avenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis

  4. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier

  5. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    It is being developed by Fibrex Medical Inc.

  6. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  7. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  8. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.

  9. Drug

    Carbomycin

    go.drugbank.com/drugs/DB11383
    ExperimentalVet approved

    The structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.

  10. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]